Summit Therapeutics SMMT Interest Expense
Discontinued — last reported Q4 '25
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Summit Therapeutics’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's interest expense?
- Summit Therapeutics (SMMT) reported interest expense of $0 in Q4 2025.
- How has Summit Therapeutics's interest expense changed year-over-year?
- Summit Therapeutics's interest expense decreased by 100.0% year-over-year, from $9K to $0.
- What is the long-term trend for Summit Therapeutics's interest expense?
- Over 2 years (2022 to 2025), Summit Therapeutics's interest expense has grown at a -100.0% compound annual growth rate (CAGR), from $4.4M to $0.
- What does interest expense mean?
- The cost of borrowing money.
- How do you interpret interest expense?
- An increase signals higher debt levels or rising interest rates, which can pressure cash flow and profitability.
- How does interest expense compare across companies?
- Compare against industry debt-to-equity standards to assess the company's financial risk profile.